Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

David Seeberger Appointed iOnctura SA Vice-president, Finance

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

David Seeberger has extensive experience in publicly-listed growth-oriented biotech and medtech companies. Before taking charge of global finance operations at iOnctura, he served as VP Head of Finance Europe at NASDAQ listed bluebird bio, and held senior financial positions at Aegerion Pharmaceuticals, InterMune Corporation and Stryker Corporation.

“David has joined iOnctura at an exciting and expansive time in the company’s development,” said Catherine Pickering, CEO of iOnctura. “As our clinical programs and commercial ambitions step through the gears, his appreciation of the wider strategic life sciences landscape and proven track record in driving early businesses forward will be invaluable.”

iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine